abstract |
The present invention relates to an Ahr receptor agonist for use in combination with at least one immune control point modulator in the treatment of cancer. The present invention also relates to a product containing an AhR receptor agonist and at least one immune checkpoint modulator as defined in any one of the preceding claims, as an association preparation for use simultaneously, separately or separately. sequentially in the treatment of cancer. |